web analytics
23.7 C
Munich
Wednesday, June 29, 2022

The Inside Scoop on Organicell Flow; Organicell Regenerative Medicine Inc (OTCMKTS: BPSR)

Organicell Regenerative Medicine Inc (OTCMKTS: BPSR) is making an explosive move up the charts after the Company announced the FDA approved two outpatient Emergency Investigational New Drug Applications (eINDs) for treating mild to moderate respiratory distress due to COVID-19. Organicell is collaborating with physicians at Landmark Hospital, a network of six hospitals located throughout the Southeast United States, to treat these patients for advanced complications associated with COVID-19

BPSR is exploding up the charts as its Organicell Flow products gain traction and show real promise in the fight against covid-19. The stock spiked to highs of $0.289 in May after the Company reported the initial positive results coming back from critically ill COVID-19 inpatients at Landmark Hospital in Athens, Georgia being treated with Organicell Flow. Treatment with Organicell Flow resulted in a remarkable improvement in their clinical status, lung and renal function confirmed by follow up chest X-rays and lab data. These patients are no longer intubated, are alert and oriented with stable vital signs and oxygenation. Other organs such as the brain, heart and liver commonly affected in patients who had the SARS-CoV-2 virus have all shown progressive improvement in their function.

Organicell Regenerative Medicine Inc (OTCMKTS: BPSR) is a clinical-stage biopharmaceutical company that harnesses the power of exosomes to develop innovative biological therapeutics for the treatment of degenerative diseases. The company’s proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. Based in South Florida, the company was founded in 2008 by Albert Mitrani, Chief Executive Officer and Dr. Mari Mitrani, Chief Scientific Officer.

The big story on Organicell is Organicell Flow; a natural and acellular product derived from amniotic fluid and is manufactured to retain the naturally occurring hyaluronic acid, proteins, and exosomes present in perinatal fluid without the addition or combination of a substance or diluent. Organicell products are manufactured in cGMP compliant labs and are tested for sterility, endotoxin levels, hyaluronic acid, protein analysis, and exosomes composition. Exosomes are nano-sized extracellular vesicles that mediate cell-to-cell communication and affect cell function and behavior. Organicell has received Emergency Compassionate Use Investigational New Drug applications (eINDs) by the FDA which allows for the immediate use of the experimental biologic.

To Find out the inside Scoop on BPSR Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

BPSR

In May, Organicell announced plans to begin the first randomized, double-blinded, placebo-controlled, phase I/II multi-center clinical trial of Organicell Flow, investigating the safety and potential efficacy of amniotic fluid sourced components for COVID-19. It is expected that this trial will begin enrollment later in the month. Find the listing of the Organicell Flow clinical trial here:

According to the August 6 press release Organicell’s first patient approved for the eIND experienced moderate chest discomfort accentuated when taking deep breaths, persistent non-productive cough and fatigue upon exertion. After receiving three doses of Organicell Flow, the patient has shown a reduction in cough and ability to breathe without pain. The second outpatient previously spent seven weeks in the hospital, was admitted to the ICU twice, received Bi-Level Positive Airway Pressure (BiPAP) treatment and continued to experienced shortness of breath after hospital discharge. Now, being treated as an outpatient, he was administered the first dose of Organicell Flow on August 4th, 2020, and to date, has reported improvements in all his symptoms.

Organicell previously announced it had successfully treated two critically ill COVID-19 inpatients at Landmark Hospital in Athens, Georgia. Since then, a third approved eIND inpatient with COVID-19 related respiratory impairment and acute kidney injury, was treated by Organicell, and the patient had a complete recovery of lung and renal function and was discharged 26 days after initiation of treatment.

CEO Albert Mitrani recently stated:  “I’m extremely proud of what the Organicell team has accomplished since we first started working on this virus in January. We are excited to now be in a position to help patients that are suffering from this horrible disease.”

We have a Monster Pick Coming. Subscribe Right Now!

Currently running up the charts BPSR is an excitng story developing in small caps; Organicell Flow continues to gain traction and shows real promise in the fight against covid-19. Treatment with Organicell Flow resulted in a remarkable improvement in their clinical status, lung and renal function confirmed by follow up chest X-rays and lab data. These patients are no longer intubated, are alert and oriented with stable vital signs and oxygenation. Other organs such as the brain, heart and liver commonly affected in patients who had the SARS-CoV-2 virus have all shown progressive improvement in their function. Organicell is collaborating with physicians at Landmark Hospital, a network of six hospitals located throughout the Southeast United States, to treat these patients for advanced complications associated with COVID-19. The Company announced plans to begin the first randomized, double-blinded, placebo-controlled, phase I/II multi-center clinical trial of Organicell Flow, investigating the safety and potential efficacy of amniotic fluid sourced components for COVID-19. It is expected that this trial will begin enrollment later in the month. We will be updating on BPSR as events unfold so make sure you are subscribed to Microcapdaily so you know what is going on with BPSR.

WAIT! Do You Want Stocks That Could Go Up 348% In Days Delivered To Your Inbox For FREE?

Disclosure: we hold no position in BPSR either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.